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Abstract
Introduction: Bcl-xL, an important member of anti-apoptotic Bcl-2 family, plays critical roles in tumor progression
and development. Previously, we have reported that overexpression of Bcl-xL was correlated with prognosis of
colorectal cancer (CRC) patients. The aim of this study was to investigate the association of Bcl-xL expression with
invasion and radiosensitivity of human CRC cells.
Methods: RT-PCR and Western blot assays were performed to determine the expression of Bcl-xL mRNA and
protein in CRC cells and normal human intestinal epithelial cell line. Then, adenovirus-mediated RNA interference
technique was employed to inhibit the expression of Bcl-xL gene in CRC cells. The proliferation of CRC cells was
analyzed by MTT and colony formation assay. The migration and invasion of CRC cells was determined by wound-
healing and tranwell invasion assays. Additionally, the in vitro and in vivo radiosensitivity of CRC cells was
determined by clonogenic cell survival assay and murine xnograft model, respectively.
Results: The levels of Bcl-xL mRNA and protein expression were significantly higher in human CRC cells than in
normal human intestinal epithelial cell line. Ad/shBcl-xL could significantly reduce the expression of Bcl-xL protein
in CRC cells. Also, we showed that adenovirus-mediated siRNA targeting Bcl-xL could significantly inhibit
proliferation and colony formation of CRC cells. Ad/shBcl-xL could significantly suppress migration and invasion of
CRC cells. Moreover, Ad/shBcl-xL could enhance in vitro and in vivo radiosensitivity of CRC cells by increasing
caspase-dependent apoptosis.
Conclusions: Targeting Bcl-xL will be a promising strategy to inhibit the metastatic potential and reverse the
radioresistance of human CRC.
Introduction
Colorectal cancer, one of the most prevalent cancers in
the world, is the second most common malignancy and
the second leading cause of cancer related mortality in
developed countries [1]. In spite of much progress made
in diagnostic and therapeutic methods, the prognosis of
CRC patients with distant metastasis still remains poor.
Therefore, it is necessary to understand the molecular
signaling mechanisms of CRC development so as to pro-
vide important insights into more effective therapeutic
strategies.
Bcl-xL, an anti-apoptotic member, plays important
roles in tumor progression and development [2]. Bcl-xL
molecule may inhibit apoptosis by maintaining the per-
meabilization status or stabilization of the outer mito-
chondrial membrane [3]. It has been reported that Bcl-xL
is overexpressed in many human cancers such as gastric
cancer, hepatocelluar cancer, prostate carcinoma, osteo-
sarcoma, breast cancer, etc [4-8]. Previously, we have
reported that high level of Bcl-xL protein is correlated
with tumor differentiation, lymph node metastasis,
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venous permeation, and Duke’s classification of CRC
patients [9]. Furthermore, patients with high Bcl-xL
expression showed poorer overall survival than those
with low Bcl-xL expression and the status of Bcl-xL pro-
tein expression might be an independent prognostic mar-
ker for CRC patients. Also, Zhang and his colleagues
report that Bcl-xL gene plays an important role in carci-
nogenesis of human colorectal carcinoma and is asso-
ciated with malignant biological behaviors of human
colorectal carcinoma [10]. Additionally, the correlation
between Bcl-xL and chemoresistance of CRC was also
reported by other researchers. Guichard’ et al showed
that short hairpin RNAs targeting Bcl-xL modulated
senescence and apoptosis following SN-38 and irinotecan
exposure in a colon cancer model [11]. Zhu and his col-
leagues found that the combination of Bcl-XL-specific
small interfering RNA and 5-FU had additive effect on
the inhibition of 5-FU-resistant cells [12]. Likewise,
Nita’et al showed that the suppression of Bcl-X(L)
expression by the specific antisense ODNs could increase
the sensitivity of CRC cells to 5-FU [13]. From these
experimental data, it was concluded that Bcl-xL might
play important roles in the chemoresistance of human
CRC. However, whether Bcl-xL affects the metastatic
capacity and radiosensitivity of CRC cells is still unclear.
To the best of our knowledge, there have been no reports
about the correlation between Bcl-xL expression and
metastasis or radioresistance of CRC cells.
In the present study, we take advantage of the RNA
interference (RNAi) technology, by using an adenoviral
construct in order to deliver small interfering RNA mole-
cules that target Bcl-xL gene. RNAi is a highly evolutio-
narily conserved mechanism of gene regulation, which
occurs at a post-transcriptional level. Here, adenovirus-
mediated siRNA targeting Bcl-xL could inhibit migration,
invasion and metastasis of CRC cells. Meanwhile, Bcl-xL
inhibition could increase in vitro and in vivo radiosensi-
tivity of CRC cell lines by increasing apoptotic cell death.
Materials and methods
Cell lines
Human colorectal cancer cell lines (SW480, HT-29,
LoVo and Colo320) and one human intestinal epithelial
cell line (HIEC) were purchased from American Type
Culture Collection (ATCC, Manassas, VA). All the cell
lines were cultured in Dulbecco’s modified Eagle’s med-
ium (DMEM) supplemented with 10% fetal calf serum
(FCS) and maintained at 37°C in a humidified chamber
with 5% CO2.
Recombinant adenovirus generation
The cDNA sequence of Bcl-xL was obtained from
GenBank (Accession No. Z23115). The siRNA target
design tools from Ambion were used to design shBcl-xL
and control shRNA (shcontrol) sequences, which were
designed and synthesized as follows: shBcl-xL, sense:5’-
GATCCCCGGAGATGCAGGTATTGGTGttcaagaga-
CACCAATACCTGCATCTCCTTTT-TGGAAA-3’; Nega-
tive control shRNA, sense: 5’-GATCCCCGGTGAGAGG
TAGGCGTTTAttcaa-gagaTAAACGCCTACCTCTCAC
CTTTTTGGAAA-3’; The sequences was subcloned into
the HindIII and BglII sites of pAdTrack adenoviral shut-
tle vector to get pAdTrack/shBcl-xLor pAdTrack/
shControl. The recombinant vectors were confirmed by
the digestion analysis of restriction endonuclease and all
inserted sequences were verified by DNA sequencing.
The resulting pAdTrack/shBcl-xLor pAdTrack/shCon-
trol vectors were linearized with PmeI and co-trans-
formed into BJ5183 cells with adenoviral backbone
vector pAdEasy-1. Positive clones were selected and
conformed by DNA miniprep and PacI digestion. Plas-
mids from correct clones were amplified by transform-
ing into DH5K cells. Adenoviral DNA (Ad/shBcl-xL or
Ad/shcontrol) was prepared by a standard alkaline lysis
procedure, and was linearized with PacI and purified by
ethanol precipitation. The packaging cell line 293 was
cultured in DMEM with 10% FBS, 100 U/mL penicillin
and 100 mg/mL streptomycin. Twenty-four hours before
transfection, cells were plated in six-well plates. Cells
were transfected with Lipofectamine 2000 plus (Invitro-
gen, USA). The next day, the medium containing the
transfection mix was replaced with fresh medium.
Transfected cells were incubated for additional period of
7~10 days and medium was changed every 2~3 days.
Virus was harvested, amplified and titered (Stratagene,
USA).
Adenovirus infection
On the day before virus infection, CRC cells were plated
in each well of six-well plates. When the cells reached
approximately 70-90% confluence, the culture medium
was aspirated and the cell monolayer was washed with
prewarmed sterile phosphate-buffed saline (PBS). Cells
were incubated with indicated virus (Ad/shcontrol or
Ad/shBcl-xL) at multiplicity of infection (MOI) of 0,
40 or 80 at 37°C, respectively. After adsorption for 2 h,
2 ml of fresh growth medium was added and cells were
placed in the incubator for additional 2-3 days. The
cells analysis and other experiments were performed.
The following experiments were performed using viruses
at such MOIs except for special indications.
Bcl-xL siRNA oligonucleotide and cell transfection
The siRNA oligonucleotide specific for Bcl-xL (siRNA/
Bcl-xL) and scrambled siRNA (siRNA/control) were pur-
chased from Ambion (Austin, TX, USA). Human color-
ectal cancer cell line (LoVo) was grown in DMEM
medium containing 10% fetal calf serum (Gibco BRL, Life
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Technology, USA) at 37°C in a humidified atmosphere
containing 5% CO2. Twenty-four hours before transfec-
tion, cells were diluted in fresh media without antibiotics
and transferred to six-well plates. LoVo cells grown to a
confluence of 40%-50% were transfected with 50-200
nmol/L (final concentration) of siRNA per well using
Lipofectamine 2000 and Opti-MEM (Invitrogen, Karls-
ruhe, Germany) media according to the manufacturer’s
recommendations. 48 h after transfection, the cells were
collected for the further researches.
Reverse Transcription (RT) - PCR assay
Total RNA was extracted from tissues using TRIzol
reagent (Invitrogen, Carsbad, CA, USA) according to the
manufacturer’s instructions. Two micrograms of RNA
were subjected to reverse transcription. The PCR primers
used were as follows: for Bcl-xL, 5’-CCCAGAAAGGATAC
AGC-TGG -3’ (forward), 5’-GCGATCCGACTCACCAA-
TAC -3’ (reverse); and for GAPDH (internal control), 5’-
GAAGGTGAAGGTCGGATGC-3’ (forward), 5’-GAA-
GATGGTGATGGGATTTC-3’ (reverse). The amplification
conditions were as follows: denaturation at 94°C for
15 min; 40 cycles of 94°C for 40 s, 56°C (for Bcl-xL) and
60°C (for GAPDH) for 1 min, 72°C for 1 min; and a final
10 min extension at 72°C. The PCR products were sepa-
rated on a 1.5% agarose gel, visualized, and photographed
under UV light.
Western blot assay
Cells were harvested and washed with cold phosphate-
buffered saline solution, and total proteins were
extracted in the extraction buffer (150 mM sodium
chloride; 50 mMTris hydrochloride, pH7.5;1%glycerol;
and1%Non-idetp-40 substitute solution). Equal amounts
of protein (15 μg per lane) from the treated cells were
loaded and electrophoresed on an 8% sodium dodecyl
sulfate (SDS) polyacrylamide gel and then electroblotted
onto nitrocellulose membrane, blocked by 5% skim
milk, and probed with the antibodies to Bcl-xL, caspase-
3 or 9, PARP, uPA and GAPDH (Santa Cruz Biotech-
nology, Santa Cruz, CA), followed by treatment with
secondary antibody conjugated to horseradish peroxi-
dase (1:5000). The proteins were detected by the
enhanced chemiluminescence system and exposed to
x-ray film.
Immunohistochemistry assay
Immunohistochemical analysis was done to study altered
protein expression in tumor tissues. Formalin-fixed, paraf-
fin-embedded tissue was freshly cut (3 mm). Sections were
incubated in a moist chamber with primary rabbit anti-
human Bcl-xL monoclonal antibody Santa Cruz Biotech-
nology, Santa Cruz, CA) for 30 min at room temperature,
followed by a secondary antibody (peroxidase labeled
polymer conjugated to goat anti-rabbit immunoglobulin)
for 30 min (DakoCytomation, Denmark). Rabbit serum
was used as negative control.
3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
The cell viability of LoVo cells was measured by a (Sigma,
USA). Above three kinds of cells (5.0 × 103/well) were
seeded into five 96-well culture plates with each plate
having all three kinds of cells (6-parallel wells/group). On
each day, 200 μL MTT (5 mg/mL) was added to each
well, and the cells were incubated for at 37°C for addi-
tional 4 h. Then the reaction was stopped by lysing the
cells with 150 μL DMSO for 5 min. Optical densities
were determined on a Versamax microplate reader
(Molecular Devices, Sunnyvale, CA) at 490 nm.
Colony formation assay
A total of 4.5 × 102 mock LoVo or LoVo infected with
Ad/shBcl-xL or Ad/shcontrol were placed in a fresh 6-
well plate with or without DDP for another 12 h and
maintained in RMPI 1640 containing 10% FBS for 2
weeks. Colonies were fixed with methanol and stained
with 0.1% crystal violet in 20% methanol for 15 min.
Wound healing assay
The LoVo cells infected with no adenovirus or adeno-
virus adenovirus (Ad/shcontrol or Ad/shBcl-xL) at multi-
plicity of infection (MOI) of 80 were seeded into 24-well
tissue culture plates. 48 h later, an artificial homogenous
wound was created onto the monolayer with a sterile
plastic 100 μL micropipette tip. After wounding, the deb-
ris was removed by washing the cells with serum-free
medium. Migration of cells into the wound was observed
at different time points. Cells that migrated into the
wounded area or cells with extended protrusion from the
border of the wound were visualized and photographed
under an inverted microscope.
Transwell assay
Transwell invasion experiments were performed with 24-
well matrigel-coated chambers from BD Biosciences
(Bedford, MA, USA). Briefly, the LoVo cells infected with
no adenovirus or adenovirus adenovirus (Ad/shcontrol
or Ad/shBcl-xL) at multiplicity of infection (MOI) of 80
were seeded into inserts at 4.0 × 103/insert in serum-free
medium and then transferred to wells filled with the cul-
ture medium containing 10% FBS as a chemoattractant.
After 24 h of incubation, non-invading cells on the top of
the membrane were removed by scraping. Invaded cells
on the bottom of the membrane were fixed, followed by
staining with 0.05% crystal violet. The number of invaded
cells on the membrane was then counted under a
microscope.
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Flow cytometry analysis of apoptosis
Cells were treated with or without DDP for another
12 h and harvested and fixed with 2.5% glutaraldehyde
for 30 minutes. After routine embedment and section,
the cells were observed under electronic microscope.
The apoptosis rates were determined using Annexin
V-FITC and PI staining flow cytometry.
Clonogenic survival assay
The cells were seeded in 24-well plates. After 24 h-incu-
bation, fresh medium was added to each well and incuba-
tion was continued for 24 h before further treatments.
One day after the viral infection, cells were trypsinized,
plated and incubated for 24 h before irradiation. The
time interval between viral infection and radiation treat-
ment was two days. Following irradiation, duplicate
cultures were incubated for 10-14 days for colony forma-
tion. Cultures were fixed with pure ethanol and stained
with 1% crystal violet in ethanol, and colonies were
counted. Surviving fraction was determined by normaliz-
ing to the plating efficiency of the untreated control cells.
For dose fractionation, cells were irradiated with a high-
dose rate 137Cs unit (4.0 Gy/min) after the viral infec-
tions, respectively.
In vivo radiotherapy assay
BALB/c nude mice were purchased from the Experi-
ment Animal Center of Nanjing Medical University and
maintained under pathogen-free conditions according to
protocols that were approved by the Jiangsu Province
Animal Care and Use Committee. LoVo cells (4.0 ×
106) suspended in 100 μl of PBS were inoculated in the
flanks of 5-week-old female BALB/c nude mice. One
week after inoculation (day 0), mice with established
tumors measuring 5-6 mm in diameter, were randomly
divided into 5 groups (5 mice/group). Two of the
groups were irradiated, and three groups remained uni-
rradiated. For the irradiated groups, intratumoral injec-
tions of 0.1 ml of PBS, 6.0 × 108 pfu of Ad/shcontrol or
Ad/shBcl-xL were repeated three times on days 1, 3,
and 5, and subsequently X-ray irradiation was per-
formed at a clinically relevant dose of 5.0 Gy on days 2,
4, and 6. For the unirradiated groups, intratumoral
injections of 0.1 ml of PBS, 6.0 × 108 pfu of Ad/shcon-
trol or Ad/shBcl-xL were administered. Tumors were
measured with a caliper gauge twice a week over a 6-
week period following the initial virus injections. Tumor
volume was calculated according to the formula: TV
(mm3) = length×width2 ×0.4. All mice were sacrificed
and s.c tumors were resected and fixed in 10%PBS. We
measured the primary tumors and performed Western
blot or immunohistochemistry for Bcl-xL protein
expression.
uPA ELISA
Extracts were diluted 1:5 in assay buffer and 100 μL ali-
quots of each extract were incubated overnight at 4°C in
precoated microtest wells. Wells were washed thoroughly
with wash buffer and a second, biotinylated antibody that
recognizes a specific epitope on uPA molecule was added
for each analysis. Wells were washed again after an incu-
bation of 1 hour and 100 μL of enzyme conjugate was
added, leading to the formation of the antibody-enzyme
detection complex. After 1 h-incubation, wells were
washed again. Then, 100 μL of perborate 3, 3’,5, 5’-tetra-
methylbenzidine substrate was added to each well and
reacted with horseradish peroxidase, producing a blue
solution. We used 50 μL of 0.5 mol/L sulfuric acid as a
stopping solution, which yielded a yellow color in the
reaction.
Statistical analysis
All statistical analyses were performed using the SPSS
17.0 statistical software. Statistical significance of experi-
mental data was determined by Student’s t-test (two-
tailed). P < 0.05 were deemed statistically significant.
Results
The expression level of Bcl-xL is higher in CRC cell lines
than in human intestinal epithelial cell line (HIEC)
Semi-quantitative RT-PCR and Western blot assays were
done to determine the expression of Bcl-xL mRNA and
protein in four human CRC cell lines (SW480, HT-29,
Colo320 and LoVo) and a human intestinal epithelial cell
line (HIEC). The expression levels of Bcl-xL mRNA and
protein were obviously higher in human CRC cell lines
than in human intestinal epithelial cell line (Figure 1A and
1B). Among CRC cell lines, the expression levels of Bcl-xL
mRNA and protein shows difference. Meanwhile, in our
previous study, we also showed that the average level of
Bcl-xL gene in colorectal cancer tissues was significantly
higher than that in corresponding nontumor colon tissues
at both transcriptional and translational levels. Thus, it
was concluded that the overexpression of Bcl-xL might
play major roles in CRC tumorigenesis and progression.
Adenovirus-mediated siRNA targeting Bcl-xL inhibits the
expression of Bcl-xL protein in CRC cells
To determine the optimal MOI for a maximal transgene
expression, LoVo cells were infected with Ad/shcontrol
or Ad/shBcl-xl at various MOIs (0, 40, 80) and exam-
ined by fluorescence microscopy. Approximately 90% of
GFP expression could be observed in LoVo cells
infected with Ad/shcontrol or Ad/shBcl-xL at 80 MOI
(data not shown). Thus, a MOI of 80 was selected as an
optimal dose for infection of CRC cells. To testify the
effect of adenovirus-mediated siRNA targeting Bcl-xL
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on the expression of Bcl-xL gene in CRC cell line,
Western blot assay was performed to detect the expres-
sion of Bcl-xL protein. The expression level of Bcl-xL pro-
tein in Ad/shBcl-xL-infected LoVo cells was decreased by
approximately 76.3% by compared to that in mock or Ad/
shcontrol-infected cells (P < 0.01; Figure 2A). Also, at 48 h
after transfection by Lipofectamine 2000, we analyzed the
expression of Bcl-xL protein in the siRNA/Bcl-xL-trans-
fected LoVo cells. Compared with mock or siRNA/con-
trol-transfected LoVo cells, the expression of Bcl-xL
protein was decreased by only 34.6% (P < 0.05; Figure 2B).
Thus, the knockdown effect of adenovirus-mediated
siRNA showed more efficient than that of siRNA oligonu-
cleotide transfected by lipofection. Next, we analyzed the
effects of adenovirus-mediated siRNA targeting Bcl-xL on
the expression of other apoptosis relevant proteins includ-
ing Bcl-2 and Mcl-1. As shown in Figure 2C, the levels of
Bcl-2 and Mcl-1 protein expression in Ad/shBcl-xL-
infected LoVo cells showed no difference compared with
those in mock or Ad/shcontrol-infected cells (P > 0.05;
Figure 2C). These data showed that adenovirus-mediated
siRNA targeting Bcl-xL could specifically and significantly
inhibit the expression of Bcl-xL gene in CRC cells.
Ad/shBcl-xL significantly suppresses the proliferation of
CRC cells
Given that Ad/shBcl-xL could effectively inhibit Bcl-xL
expression, its effects on the proliferation of CRC cells
in vitro were determined. As shown in Figure 3A, com-
pared with Ad/shcontrol or mock infection, Ad/shBcl-
xL significantly decreased the viability of LoVo cells in a
time-dependent manner, and the average proliferation
inhibition rates at 3, 4, and 5 days were 39.2%, 42.9%,
and 44.3%, respectively (P < 0.05). Additionally, Ad/
shBcl-xL could significantly reduce the colony formation
of LoVo cell by approximately by 35.4% (P < 0.01;
Figure 3B). These results suggested that siRNA-mediated
inhibition of Bcl-xL could suppress the proliferation of
CRC cells.
Ad/shBcl-xL significantly reduces the migration and
invasion of CRC cells
Prior researches show that Bcl-xL is an anti-apoptotic
protein of Bcl-2 family involved in the regulation and
promotion of tumor cell survival, but whether Bcl-xL
affects the process of tumor invasion and metastasis is
still unclear. To investigate the effect of Bcl-xL inhibition
on migration and invasion of CRC cells, we performed
the scratch-wound and matrigel transwell assays.
Scratch-wound assay on confluent monolayers was used
as a way of determining cell migration. The mock LoVo
or LoVo cells infected with Ad/shcontrol or Ad/shBcl-xL
were reseeded in the six-well culture wells with the same
cell number for the wound healing assay. At 48 h after
wounding, the healing ability of Ad/shBcl-xL-infected
LoVo cells significantly lagged behind the mock LoVo or
Ad/shcontrol-infected LoVo cells (Figure 4A). Matrigel
transwell assay was done to analyze the changes of in
vitro invasion capacity of LoVo cells (Figure 4B). Ad/
shBcl-xL-infected LoVo cells showed a significantly
decreased invasion capacity compared with mock LoVo
cells or Ad/shcontrol-infected LoVo cells. A representa-
tive experiment demonstrates a marked reduction in the
migration of LoVo cells after Ad/shBcl-xL infection com-
pared with mock or Ad/shcontrol infection (P < 0.05).
The results were quantified from three independent
Figure 1 The expression of Bcl-xL mRNA and protein in four human CRC cell lines (SW480, HT-29, LoVo and Colo320) and one
intestinal epithelial cell line (HIEC) by RT-PCR (A) and Western blot assay (B). GAPDH was used as an internal control.
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experiments confirming significant decrease in the num-
ber of Bcl-xL-ablated LoVo migrating through collagen.
These data indicated that adenovirus-mediated siRNA
targeting Bcl-xL could significantly inhibit in vitro migra-
tion and invasion of CRC cells.
Ad/shBcl-xL significantly increases the in vitro sensitivity
of CRC cells to irradiation
Previously, we have reported that the overexpression of
Bcl-xL could affect the sensitivity of osteosarcoma cells
to irradiation, but the association of Bcl-xL expression
with the radiosensitivity of CRC cells is still unclear. To
investigate the radiosensitizing effects of adenovirus-
mediated siRNA targeting Bcl-xL on CRC cells, a colony-
forming assay was performed. The surviving fraction of
the cells infected with Ad/shBcl-xL at a MOI of 80 was
significantly lower than that of mock LoVo or Ad/shcon-
trol-infected LoVo cells at doses of 4.0 and 10.0 Gy
(Figure 5A). Then, flow cytometry was performed to ana-
lyze the changes of apoptosis in mock LoVo or LoVo
cells infected with Ad/shcontrol or Ad/shBcl-xL com-
bined with or without irradiation (8.0 Gy). As shown in
Figure 2 The expression of Bcl-xL protein in CRC cells was significantly downregualted after adenovirus infection. A. Western blot
analysis of Bcl-xL protein expression in mock LoVo or LoVo infected with Ad/shcontrol or Ad/shBcl-xL. B. Western blot analysis of Bcl-xL protein
expression in mock LoVo or LoVo transfected with siRNA/control or siRNA/Bcl-xL. C. Western blot analysis of Bcl-2 and Mcl-1 protein expression
in mock LoVo or LoVo infected with Ad/shcontrol or Ad/shBcl-xL. GAPDH was used to an internal control. Each assay was performed at least in
triplicate. **P < 0.01 and *P < 0.05 vs mock.
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Figure 5B, the apoptotic rate of Ad/shBcl-xL-infected
LoVo cells was obviously increased by approximately
11.4% compared with mock LoVo cells (P < 0.05). The
apoptotic rates of mock LoVo or Ad/shcontrol-infected
LoVo cells treated with 8.0-Gy irradiation alone were
approximately 12.6% and 14.2%, respectively. However,
the apoptotic rate of Ad/shBcl-xL-infected LoVo cells
increased to 23.6% (P < 0.05; Figure 5C). Thus,
adenovirus-mediated siRNA targeting Bcl-xL could
enhance the radiosensitivity of CRC cells by the increase
of radiation-induced apoptosis.
Ad/shBcl-xL significantly increases the in vivo sensitivity
of CRC cells to irradiation
Firstly, Western blot assay was performed to detect the
expression of Bcl-xL protein in LoVo xenografts on day 7
Figure 3 Effects of Ad/shBcl-xL on the proferation and colony formation of CRC cells. A. The proliferation of LoVo cells was measured by
MTT assay. The cell proliferation of LoVo infected with Ad/shBcl-xL was significantly inhibited in a time-dependent manner. B. The colony
number was counted in three different wells at 14 days after seeded, and the averaged number was plotted. The experiments were repeated
thrice and similar results were obtained. Representative data are shown. Each assay was performed at least in triplicate. *P < 0.05 vs mock.
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and 42 post injection of adenovirus. As shown in Figure
6A, the expression of Bcl-xL protein in the turmors in
Ad/shBcl-xL-treated group was significantly downregu-
lated compared with PBS or Ad/shcontrol-treated group.
Immunohistochemistry assay was performed to analyze
the expression of Bcl-xL protein in tumor tissues from
LoVo xenografts. As shown in Figure 6B, the tumors in
Ad/shBcl-xL-treated group showed significant decreases
in the cytoplasmic immunostaining of Bcl-xL protein
compared with PBS or Ad/shcontrol-treated group. Next,
we attempted to investigate the effect of siRNA-mediated
knockdown of Bcl-xL on the in vivo radiosensitivity of
CRC cells. Nude mice with established tumors xenografts
were treated with PBS or adenovirus (Ad/shBcl-xL or
Figure 4 Effects of Ad/shBcl-xL on migration and invasion of LoVo cells. A. Scratch wound-healing assay. The cells were infected with
mock, Ad/shcontrol or Ad/shBcl-xL as indicated. 72 h after wounding, cells with extended membrane protrusion moved into the wounded
areas. Mock: no adenovirus. B. Transwell invasion assay. The invasive LoVo cells were stained and counted under microscope and quantitative
results for the transmembrane ability of each group of cells (n = 3). *P < 0.05 vs mock.
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Ad/shcontrol), followed by 4.0Gy-local radiotherapy. A
representative growth curve of LoVo xenografted tumors
after various treatment was shown in Figure 6C. Ad/
shBcl-xL plus irradiation led to a significant suppression
of tumor growth compared with Ad/shcontrol plus irra-
diation or Ad/shBcl-xL alone (P < 0.05). On day 42, the
tumor-inhibition rates of Ad/shBcl-xL group, Ad/shcon-
trol plus irradiation group and Ad/shBcl-xL plus irradia-
tion group were 20.2, 35.1 and 56.8%, respectively (P <
0.05; Figure 6D). These experimental data showed that
adenovirus-mediated siRNA targeting Bcl-xL could
increase the in vivo radiosensitivity of CRC cells, which
showed that combined Bcl-xL downregulation with
radiotherapy could lead to a stronger anti-tumor effect
for human CRC.
Effects of Ad/shBcl-xL on apoptosis or metastasis-related
proteins in CRC cells
The Bcl-2 family members are important regulators of the
mitochondrial pathway of apoptosis. Then, we analyzed
the effect of siRNA-mediated Bcl-xL inhibition on the
expression of caspase-9, caspase-3 and PARP protein.
Western blot assay showed that Ad/shBcl-xL could signifi-
cantly induce activation of caspase-9, caspase-3 and PARP
(Figure 7A). Additionally, we showed that Ad/shBcl-xL
could significantly inhibit the expression of uPA protein
Figure 5 Effects of Ad/shBcl-xL on the in vitro sensitivity of LoVo cells to irradiation. A. Clonogenic survival after varying doses of
irradiation exposure. The mock, Ad/shcontrol or Ad/shBcl-xL-infected LoVo cells were irradiated followed by a further incubation for 24 h at 37°C
before trypsinization and plating for clonogenic survival. After 10-14 days incubation, colonies were stained, and the surviving fraction was
determined. The log survival was formed to the number of cells plated, after correcting for plating efficiency. B. Flow cytometry analysis of
apoptosis in mock LoVo or LoVo cells infected with Ad/shcontrol or Ad/shBcl-xL. C. Flow cytometry analysis of apoptosis in mock, Ad/shcontrol
or Ad/shBcl-xL-infected LoVo combined with irradiation treatment (8.0 Gy). Error bars, the mean ± SD in three experiments (n = 3). *P < 0.05 vs
mock.
Yang et al. World Journal of Surgical Oncology 2011, 9:117
http://www.wjso.com/content/9/1/117
Page 9 of 13
compared with control cells (Figure 7A). Then, we ana-
lyzed the changes of uPA activity. As shown in Figure 7B,
compared with mock LoVo cells, the activity of uPA in
Ad/Bcl-xL-infected LoVo cells was significantly reduced
by approximately 54.6% (Figure 7B). Therefore, the
changes of those proteins might be involved in Bcl-xL-
induced malignant phenotypes of CRC cells.
Discussion
CRC is the third most commonly diagnosed cancer
around the world and the incidence of CRC in China is
lower than that in the west countries, but has increased
in recent years and become a substantial cancer burden
in China, particularly in the more developed areas such
as East Guangdong [14]. Despite the current surgical
techniques and chemo- or radiotherapy that have made
significant improvements, the cure rate for advanced
CRC remains low and the morbidity remains high.
Therefore, progresses made in CRC therapy might result
from a fully understanding of its pathogenesis and biolo-
gical characteristics.
The Bcl-2 family comprises a group of structurally
related proteins that play a fundamental role in the regula-
tion of the intrinsic pathway by controlling mitochondrial
membrane permeability and the release of the pro-apopto-
tic factor, cytochrome c [15]. Usually, those proteins were
divided into two classes: those that inhibit apoptosis (Bcl-
2, Bcl-xL, Mcl-1, et al); those that promote apoptosis
Figure 6 Effects of Ad/shBcl-xL on the in vivo sensitivity of LoVo cells to irradiation. A. Protein samples extracted from tumors at day 7 or
42 were determined using Western blot analysis for Bcl-xL expression levels. GAPDH was used as a loading control. B. Immunohistochemistry
was performed to detect the expression of Bcl-xL protein in tissues of LoVo tumors treated with PBS, Ad/shcontrol or Ad/shBcl-xL at day 7 or 42.
C. Proliferation of tumors in the mice injected with LoVo cells treated with PBS, Ad/shcontrol or Ad/shBcl-xL. D. Dectection of average tumor size
at day 42 after the inoculation of LoVo cells treated with PBS, Ad/shcontrol or Ad/shBcl-xL. All experiments were performed in triplicate (n = 3).
*P < 0.05 vs mock.
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(BAK, Bax, Bcl-xs, et al) [16]. Bcl-xL is an important novel
member of anti-apoptotic Bcl-2 family, which has been
reported to play critical roles in tumor progression, devel-
opment and chemo- or radioresistance [17-19]. Tumor
metastasis is a highly complex process involving the survi-
val of tumor cells, both in the blood stream and within
specific organs [20]. It has been reported that cell-death or
survival are determined by a number of gene products
Figure 7 Effects of Ad/shBcl-xL on the expression of apoptosis or metastasis-related proteins in LoVo cells. A. Western blot detection of
active caspase-9 (p47 and p37), caspase-3 (p32 and p17), PARP (p116 and p85) and uPA protein expression. B. Analysis of activity of uPA in
mock LoVo or LoVo cells infected with Ad/shcontrol or Ad/shBcl-xL. The cells in 24-well plates (5.0 × 105/well) were cultured, starved in serum-
free medium overnightand. Measurements were made in three separate experiments, and data are shown as mean ± standard deviation. *P <
0.05 vs mock. OD: optical density.
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from an expanding family of the Bcl-2 gene. In other
researches, Bcl-xL was found to be correlated with metas-
tasis of tumor cells. Rubio N and his colleagues reported
that overexpression of Bcl-x(L) could counteract the proa-
poptotic signals in the microenvironment and favor the
successful development of metastasis in specific organs
[21]. Additionally, Fernández’ et al showed that Bcl-xL
expression in breast cancer cells could increase metastatic
activity and this advantage could be created by inducing
resistance to apoptosis against cytokines, increasing cell
survival in circulation, and enhancing anchorage-indepen-
dent growth [22]. Meanwhile, this research group also
showed that overexpression of Bcl-xL in human breast
cancer cells enhanced organ-selective lymph node metas-
tasis [23]. In our previous study, we showed that the over-
expression of Bcl-xL was significantly associated with
lymph node metastasis and venous permeation of CRC
patients [9]. Zhang and his colleagues also reported that
the expression of Bcl-xL was associated with the patholo-
gical grade, lymph node metastasis and Duke’s stage of
colorectal carcinoma [10]. However, the correlation of
Bcl-xL expression with invasion and metastasis of CRC
cells need to be further elucidated.
RNA interference (RNAi) by double stranded RNA
(dsRNAs) molecules of approximately 20-25 nucleotides
termed short interfering (siRNAs) is a powerful method
for preventing the expression of a particular gene [24].
Plasmid and viral vectors producing siRNA using the
polymerase III promoter offer more efficient siRNA
delivery and are showing promise both in vitro and in
vivo [25]. In our research, adenovirus-mediated siRNA
targeting Bcl-xL could significantly inhibit the expression
of Bcl-xL in human CRC cells. Adenovirus-mediated
siRNA targeting Bcl-xL could significantly inhibit prolif-
eration and colony formation in CRC cells. Moreover,
downregulation of Bcl-xL significantly inhibited CRC cell
migration in response to wound scratch and impaired the
ability of CRC cells to invade across a Matrigel Layer.
Subsequently, we investigated the possible molecular
mechanisms by which Bcl-xL may enhance tumor inva-
sion. The urinary-type plasminogen activator, or uPA,
regarded as the critical trigger for plasmin generation
during cell migration and invasion, is strongly upregu-
lated in various malignancies including colorectal cancers
[26]. Previously, our and others studies have shown that
Bcl-xL is upregulated starting from the earliest stages of
dysplasia, we hypothesized that the uPA expression
might be related to the dysregulated expression of Bcl-xL
in CRC. In our reports, we showed that siRNA-mediated
Bcl-xL inhibition could significantly downregulate the
expression of uPA protein. The activity of uPA in Ad/
shBcl-xL-infected LoVo cells was significantly reduced,
which suggested that the Bcl-xL-mediated invasive
behavior of CRC cells might be associated with increased
activity of uPA. However, how Bcl-xL could affect the
expression and activity of uPA in CRC cells still remains
unclear and needs to be elucidated in future researches.
Currently, radiotherapy has been an integral part of
the preoperative treatment of rectal cancers. However,
only a minority of patients achieve a complete patholo-
gic response to therapy because of radioresistance of
these tumors [27]. Previously, we have shown that the
overexpression of Bcl-xL is associated with radioresis-
tance of human osteosarcoma cells. In other human
cancers, the association of Bcl-xL expression and radio-
sensitivity of tumor cells is also studied. Wang’ et al
showed that siRNA-mediated Bcl-xL downregulation
could lead to the increased sensitivity of prostate cancer
cells to radiation [28]. Masui, et al showed that the anti-
sense oligonucleotide against Bcl-XL could be a good
therapeutic tool for radiosensitization of pancreatic can-
cer [29]. Streffer and his colleagues showed that BCL-2
family protein expression (Bcl-xL and BAX) could mod-
ulate radiosensitivity in human glioma cells and targeted
alterations in BCL-2 family protein expression might be
a promising strategy to improve the therapeutic efficacy
of radiotherapy for gliomas [30]. However, up to date,
there have been no reports about the associations of
Bcl-xL expression and radiosensitivity of human CRC
cells. In this study, Ad/shBcl-xL could increase the
radiosensitivity of CRC cells not only in vitro but also in
vivo, which might be mainly associated with caspase-
dependent apoptosis enhancement.
In conclusion, we have shown for the first time that
adenovirus-mediated siRNA targeting Bcl-xL could inhi-
bit proliferation and enhance radiosensitivity of human
CRC cells. Moreover, our results also showed that Bcl-
xL played an important role in CRC cell invasion, which
might be mediated by uPA. Therefore, Bcl-xL has
potential of being a novel molecular target for the treat-
ment of human CRC.
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